Artemisinin‐based combination therapies for uncomplicated malaria
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
There has been a relentless increase in resistance of malaria parasites to conventional antimalarial drugs, including chloroquine, sulfadoxine-pyrimethamine and mefloquine. In response to this situation, short-course artemisinin-based combination therapies (ACTs) have been developed. The World Health Organization has endorsed ACT as first-line treatment where the potentially life-threatening parasite Plasmodium falciparum is the predominant infecting species. ACTs combine the rapid schizontocidal activity of an artemisinin derivative (artesunate, artemether or dihydroartemisinin) with a longer-half-life partner drug. Although the use of chloroquine and sulfadoxine-pyrimethamine as partners in ACT improves their efficacy, this may only have value as a short-term measure in patients with a degree of immunity to malaria. Alternative currently available partner drugs include mefloquine, lumefantrine and piperaquine. Artesunate-mefloquine is highly effective but is expensive and side effects (mainly neurotoxicity) can be problematic. Artemether-lumefantrine, the only ACT available in Australia, appears less effective than artesunate-mefloquine and needs to be administered with food to ensure adequate bioavailability. Dihydroartemisinin-piperaquine is highly effective, well tolerated and relatively inexpensive. The goal of potent, safe, easy-to-administer and inexpensive ACTs may see trioxolanes in place of artemisinin derivatives, as well as novel partner drugs such as pyronaridine or naphthoquine, in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nosten, F., van Vugt, M., Price, R., Luxemburger, C., Thway, K., Brockman, A., McGready, R., ter Kuile, F., Looareesuwan, S., & White, N. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02505-8 · Cited by 500
Cited by
Artemisinin-Based Combination Treatment of Falciparum Malaria
Nosten, F., & White, N. J. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.181 · Cited by 673
The Antiviral Activities of Artemisinin and Artesunate
Efferth, T., Romero, M. R., Wolf, D. G., Stamminger, T., Marin, J. J. G., & Marschall, M. (2008) · Clinical Infectious Diseases · doi:10.1086/591195 · Cited by 503
Discovery, mechanisms of action and combination therapy of artemisinin
Cui, L., & Su, X.-Z. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.68 · Cited by 371
Efferth, T. (2007) · Planta Medica · doi:10.1055/s-2007-967138 · Cited by 269
Zhang, L., Jing, F., Li, F., Li, M., Wang, Y., Wang, G., Sun, X., & Tang, K. (2009) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20080068 · Cited by 206
Metadata
- Authors
- Davis, T. M. E., Karunajeewa, H. A., & Ilett, K. F.
- Venue
- Medical Journal of Australia
- Publisher
- AMPCo
- Published
- 2005-02
- Volume
- 182
- Issue
- 4
- Pages
- 181-185
- ISSN
- 0025-729X (ISSN-L)
- 1326-5377
- OpenAlex
- W2145130342
- Cited by
- 155
- References
- 1
- FWCI
- 16.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Artemisinin‐based combination therapies for uncomplicated malaria. https://app.cochat.ai/papers/10.5694/j.1326-5377.2005.tb06650.x
- The paper
- Davis, T. M. E., Karunajeewa, H. A., & Ilett, K. F. (2005). Artemisinin‐based combination therapies for uncomplicated malaria. Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2005.tb06650.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.